NCT03798626: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers |
|
|
| Active, not recruiting | 1 | 167 | Europe, Canada, Japan, US, RoW | Gevokizumab, VPM087, Bevacizumab, Modified FOLFOX6, oxaliplatin, leucovorin, 5-fluorouracil, FOLFIRI, irinotecan, leucovorin, 5-fluorouracil, Ramucirumab, Paclitaxel, Cabozantinib | Novartis Pharmaceuticals | Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma | 03/23 | 01/25 | | |
